68 results
424B3
QNRX
Quoin Pharmaceuticals Ltd
10 May 24
Prospectus supplement
4:10pm
and development of the Company’s therapeutic targets and its other operating requirements until it achieves commercial profitability, if ever … and is subject to significant uncertainty. Additional financing will be required to complete the research and development of our therapeutic targets
POS AM
QNRX
Quoin Pharmaceuticals Ltd
29 Mar 24
Prospectus update (post-effective amendment)
4:11pm
financing will be required to complete the research and development of our therapeutic targets and our other operating requirements, which may … cash bonus may be awarded to executive officers upon the attainment of pre-set periodic objectives and individual targets. The annual cash bonus that may
424B4
QNRX
Quoin Pharmaceuticals Ltd
6 Mar 24
Prospectus supplement with pricing info
5:07pm
to significant uncertainty. Additional financing will be required to complete the research and development of our therapeutic targets and our other … of our therapeutic targets and our other operating requirements, which may not be available at acceptable terms, if at all. If we are unable to obtain
424B3
tqor 3klm0ty6q16u
4 Mar 24
Prospectus supplement
5:27pm
424B3
5ng3h p5k7vxwx1v3mh
9 Nov 23
Prospectus supplement
5:15pm
424B3
k7ockeo0l2
14 Sep 23
Prospectus supplement
4:38pm
8-K
EX-10.1
0cn9e8t26
12 Sep 23
Entry into a Material Definitive Agreement
6:01pm
424B3
77qbm9a20is5js4u
3 Aug 23
Prospectus supplement
4:51pm
424B3
dbrfsh8
9 May 23
Prospectus supplement
4:03pm
10-Q
745w 9gdfo3d1obxw
9 May 23
Quarterly report
3:03pm
424B3
5dgo5dxjpfvtqzdllgo
10 Nov 22
Prospectus supplement
12:45pm
424B3
xbntyz
10 Nov 22
Prospectus supplement
12:43pm
6-K
EX-99.1
xmmtzy2wsq8b
10 Nov 22
Current report (foreign)
11:08am
6-K
EX-99.2
ossp985fl4k 6mdm
10 Nov 22
Current report (foreign)
11:08am